Lupin Limited, a leading global pharmaceutical company, announced that its subsidiary Pharma Dynamics, entered into a commercial agreement with Cresco Pharma. The agreement is for cannaQIX10, a hemp oil. According to the press release announcing the agreement, Pharma Dynamics receives sole distribution rights over cannaQIX10 across various countries, including Botswana, , South Africa, Namibia, Zimbabwe, Lesotho, and Uganda.
cannaQix10 is not one product, but a range of products, that are hemp-oil based nutraceuticals. The products feature full-spectrum organic hemp oil and CBD, zinc, and vitamins, that together work to mitigate stress, support nervous and mental functions, and more. Further, the products are free of sugar and THC. Another quality of the product is that it is user-friendly, features precise dosage control, and can provide users with a stable and reliable effect over the course of several days. The press release further indicates that the product has been developed through Good Manufacturing Practices, it is produced in Switzerland, and features a high-quality “Swiss Made” label.
Erik Roos, the CEO of Pharma Dynamics, stated in the press release
“Creso Pharma is globally recognized as a leader in the production of cannabis products with distribution agreements already in place in various countries in Europe and Asia-Pacific. The company cultivates its cannabis at its state-of-the-art Mernova Medical facility in Windsor, Nova Scotia and its pharmaceutical leadership team ensures cutting edge science and research to develop, innovative cannabis and hemp derived products. We hope that this agreement will form the foundation of a longstanding relationship as we grow our footprint from nutraceuticals into the scheduled market as well.”
Dr. Miri Halperin Wernli, the co-founder and CEO of Cresco Pharma, also shared in the press release,
“We are encouraged to see a wide range of opportunities opening up to bring premium hemp oil nutraceutical products to customers in South Africa.”